Results 111 to 120 of about 16,194 (165)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India. [PDF]

BMC Infect Dis
Bakshi S, Dutta S, Biswas A, Das R, Nath S, Ghosh A, Baskey U, Sadhukhan PC.   +7 more
europepmc   +1 more source

Hepatitis C virus care continuum: integrating point of care RNA assay and direct acting antivirals. [PDF]

EXCLI J
Fatima R.
europepmc   +1 more source

The Impact of Organic Anion-Transporting Polypeptide (OATP) Variants on the Side Effects of Direct-Acting Antivirals in Hepatitis C Patients. [PDF]

Cureus
Altintas Z, Altintas E.
europepmc   +1 more source

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C. [PDF]

Front Pharmacol
Turcu-Stiolica A, Doica IP, Ungureanu BS, Subtirelu MS, Florescu DN, Turcu-Stiolica RA, Rogoveanu I, Gheonea DI.   +7 more
europepmc   +1 more source

Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk. [PDF]

Cancers (Basel)
Fassio E, Colombato L, Gualano G, Perez S, Puga-Tejada M, Landeira G.   +5 more
europepmc   +1 more source

Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antiviral resistance and direct-acting antiviral agents for HCV

Antiviral Therapy, 2012
Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development. DAA treatment of HCV infection, however, leads to the selection of viral variants (produced by the error-prone HCV polymerase) that are resistant to the DAA agent in use ...
Aloia, A., Locarnini, S., Beard, M.
openaire   +3 more sources

Benefits of Direct-Acting Antivirals for Hepatitis C

Annals of Internal Medicine, 2017
Emerging data show that direct-acting antivirals (DAAs) improve clinical outcomes in hepatitis C virus (HCV).
Anna S, Lok, Raymond T, Chung, Hugo E, Vargas, Arthur Y, Kim, Susanna, Naggie, William G, Powderly   +5 more
openaire   +2 more sources

Management of direct-acting antiviral agent failures

Journal of Hepatology, 2015
Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance.
Maria, Buti, Mar, Riveiro-Barciela, Rafael, Esteban   +2 more
openaire   +2 more sources

Direct-acting antiviral retreatment patterns for hepatitis C

Journal of Managed Care & Specialty Pharmacy, 2022
BACKGROUND: Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However, limited research exists to characterize rates of retreatment across different DAA agents or potential factors that may increase retreatment risk.
Shaquib Al, Hasan, Daniel G, Dauner, Abhijeet, Rajpurohit, Joel F, Farley   +3 more
openaire   +2 more sources